Wenjun Chen
Guangzhou Shi, China
Wenjun Chen, born 1985 in Guangzhou, China. He was photo editor and photographer in magazines before, and now he is a freelance photographer, videographer and co founder of May and June Studio, currently based in Guangzh…
Seen in Mdpi, Nature, Tandfonline +12 more
Nerve Block or Wound Infiltration with Liposomal Bupivacaine for Postoperative Pain Management in Open Orthopedic Surgery: A Meta-Analysis of 38 Randomized Controlled Trials Involving 3,389 Patients
Reporting style, Factual: Predominantly factual systematic review and meta-analysis reporting pooled results from randomized controlled trials, with limited interpretive discussion.
A meta-analysis of 38 randomized controlled trials involving 3,389 patients found that liposomal bupivacaine produced a small reduction in pain scores on postoperative day 2 and a borderline reduction on day 1, with some benefits in specific procedures such as total knee arthroplasty and bunion surgery. Across studies, it did not significantly reduce total or daily opioid consumption, adverse events, patient satisfaction, or hospital stay compared with conventional analgesics. Substantial heterogeneity, risk of bias, and evidence of publication bias in several outcomes limit confidence in the findings, supporting the need for larger, higher-quality trials and longer-term safety assessment.
MUC13 promotes cisplatin resistance in intrahepatic cholangiocarcinoma through regulation by histone H3K18 lactylation
Reporting style, Factual: Predominantly factual scientific research reporting experimental findings, with limited claims about translational potential.
The study identifies a positive feedback loop linking MUC13, histone H3K18 lactylation, glycolytic reprogramming and cisplatin resistance in intrahepatic cholangiocarcinoma. MUC13 activates the β-catenin/c-Myc pathway, increasing GLUT1 and glycolytic enzyme expression, lactate production and H3K18 lactylation at the MUC13 promoter. This reinforces MUC13 expression and drug resistance. Inhibiting LDHA with GSK2837808A disrupted the loop, reduced cisplatin tolerance in vitro and in vivo, and sensitized patient-derived organoids, indicating a potential therapeutic vulnerability.
